Generate Biomedicines, Inc.
GENB
$13.19
$0.413.21%
NASDAQ
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Net Income | -47.41% | ||||
| Total Depreciation and Amortization | -4.13% | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | 232.86% | ||||
| Change in Net Operating Assets | -75.76% | ||||
| Cash from Operations | -51.17% | ||||
| Capital Expenditure | -403.46% | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -435.79% | ||||
| Cash from Investing | -444.14% | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | 57.86% | ||||
| Issuance of Common Stock | 77,023.40% | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | 900.00% | ||||
| Cash from Financing | 1,742.86% | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | -10.13% | ||||